Skip to main content
SpringerLink
Log in

Extrapyramidale Nebenwirkungen bei neuroleptischer Therapie

  • Conference paper
Leitlinien neuroleptischer Therapie

Zusammenfassung

Der Nutzen einer neuroleptischen Therapie kann in erster Linie durch extrapyramidale Nebenwirkungen eingeschränkt werden, da diese das subjektive Erleben der Patienten beeinträchtigen können, häufig zu einem vorzeitigen Abbruch der Behandlung führen und therapeutisch nicht immer günstig zu beeinflussen sind. Im folgenden soll auf einige kontrovers diskutierte Aspekte extrapyramidaler Nebenwirkungen ausführlicher eingegangen werden, und es sollen Befunde eigener klinisch-experimenteller Studien vorgestellt werden.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Adler L, Angrist E, Peselow E, Corvin J, Maslansky R, Rotrosen J (1986) A controlled assessment of propranolol in the treatment of neuroleptic-induced akathisia. Br J Psychiatry 149:42–45

    Article  PubMed  CAS  Google Scholar 

  • Ayd FJ (1983) Early-onset neuroleptic-induced extrapyramidal reactions: a second survey 1961–1981. In: Coyle JT, Enna SJ (eds) Neuroleptics: neurochemical, behavioral and clinical perspectives. Raven, New York

    Google Scholar 

  • Baldessarini RJ, Davis JM (1980) What is the best maintenance dose of neuroleptics in schizophrenia? Psychiatry Res 3:115–122

    Article  PubMed  CAS  Google Scholar 

  • Barnes TRE (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154:672–676

    Article  PubMed  CAS  Google Scholar 

  • Barnes TRE, Braude WM (1985) Akathisia variants and tardive dyskinesia. Arch Gen Psychiatry 42:874–878

    Article  PubMed  CAS  Google Scholar 

  • Barnes TRE, Kidger T, Gore SM (1983) Tardive dyskinesia: a 3-year follow-up study. Psychol Med 13:71–81

    Article  PubMed  CAS  Google Scholar 

  • Branchey MC, Branchey LB, Richardson MA (1981) Effects of neuroleptic adjustment on clinical condition and tardive dyskinesia in schizophrenic patients. Am J Psychiatry 138:608–612

    PubMed  CAS  Google Scholar 

  • Braude WM, Barnes TRE (1983) Late-onset akathisia — an indicant of covert dyskinesia: two case reports. Am J Psychiatry 140:611–612

    PubMed  CAS  Google Scholar 

  • Braude WM, Barnes TRE, Gore SM (1983) Clinical characteristics of akathisia. A systematic investigation of acute psychiatric inpatient admissions. Br J Psychiatry 143:139–150

    Article  PubMed  CAS  Google Scholar 

  • Casey DE (1985) Spontaneous and tardive dyskinesia: clinical and laboratory studies. J Clin Psychiatry 46:42–47

    PubMed  CAS  Google Scholar 

  • Casey DE, Keepers GA (1988) Neuroleptic side effects: acute extrapyramidal syndromes and tardive dyskinesia. In: Casey DE, Christensen AV, Gerlach J (eds) Psychopharmacology: current trends. Psychopharmacology, series 5. Springer, Berlin Heidelberg New York Tokyo

    Google Scholar 

  • Casey DE, Povlsen UJ, Meidahl B, Gerlach J (1986) Neuroleptic-induced tardive dyskinesia and parkinsonism: changes during several years of continuing treatment. Psychopharmacol Bull 22:250–253

    PubMed  CAS  Google Scholar 

  • Chouinard G, Annable L, Ross-Chouinard A, Nostores JN (1979) Factors related to tardive dyskinesia. Am J Psychiatry 136:79–83

    PubMed  CAS  Google Scholar 

  • Csernansky JG, Grabowski K, Cervantes J, Kaplan J, Yesavage JA (1981) Fluphenazine decanoate and tardive dyskinesia: a possible association. Am J Psychiatry 138:1362–1365

    PubMed  CAS  Google Scholar 

  • Davis JM, Schaffer CM, Killian GA, Kinard C, Chan C (1980) Important issues in the drug treatment of schizophrenia. Schizophr Bull 6:70–87

    PubMed  CAS  Google Scholar 

  • Dencker SJ (1984) The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective. J Clin Psychiatry 45:22–27

    PubMed  CAS  Google Scholar 

  • Drake RE, Ehrlich J (1985) Suicide attempts associated with akathisia. Am J Psychiatry 142:499–501

    PubMed  CAS  Google Scholar 

  • Fleischhacker WW, Miller CH, Bergmann KJ (1989 a) Die neuroleptikainduzierte Akathisie. Nervenarzt 60:719–723

    PubMed  CAS  Google Scholar 

  • Fleischhacker WW, Bergmann KJ, Perovich R, Pestreich LK, Borenstein M, Lieberman JA, Kane JM (1989 b) The Hillside Akathisia Scale: a new rating instrument for neuroleptic-induced akathisia. Psychopharmacol Bull 25:222–226

    PubMed  CAS  Google Scholar 

  • Gelenberg AJ (1976) Computerized tomography in patients with tardive dyskinesia. Am J Psychiatry 133:578–579

    PubMed  CAS  Google Scholar 

  • Gelenberg AJ, Doller JC, Schooler NR, Mieske M, Severe J, Mandel MR (1979) Acute extrapyramidal reactions with fluphenazine hydrochloride and fluphenazine decanoate. Am J Psychiatry 136:217–219

    PubMed  CAS  Google Scholar 

  • Gibb WRG, Lees AJ (1986) The clinical phenomenon of akathisia. J Neurol Neurosurg Psychiatry 49:861–866

    Article  PubMed  CAS  Google Scholar 

  • Gibson AC (1981) Incidence of tardive dyskinesia in patients receiving depot neuroleptic injection. Acta Psychiatr Scand [Suppl] 291:111–114

    Article  CAS  Google Scholar 

  • Glazer WM (1984) Depot fluphenazine: risk/benefit ratio. J Clin Psychiatry 45:28–35 (5 Sec 2)

    PubMed  CAS  Google Scholar 

  • Goldberg SC, Shenoy RS, Julius D, Hamer RM, Ross B, Minton T, Spiro M (1982) Do long-acting injectable neuroleptics protect against tardive dyskinesia? Psychopharmacol Bull 18:177–179

    PubMed  CAS  Google Scholar 

  • Greil W, Haag H, Rossnagl G, Rüther E (1984) Effect of anticholinergics on tardive dyskinesia. Br J Psychiatry 145:304–310

    Article  PubMed  CAS  Google Scholar 

  • Haag H, Greil W, Rüther E (1987) Zusammenhang zwischen Spätdyskinesie und verschiedenen Variablen der neuroleptischen Behandlung. In: Heinrich K, Klieser E (Hrsg) Probleme der neuroleptischen Dosierung. Schattauer, Stuttgart New York

    Google Scholar 

  • Heinrich K (1988) Nebenwirkungsgeleitete Pharmakotherapie in der Psychiatrie. MMW 130:699–700

    Google Scholar 

  • Heinrich K, Lehmann E (1988) Fundamentals and results of controlled studies in neurolept-anxiolysis. Eur J Psychiatry 2:96–102

    Google Scholar 

  • Heinrich K, Wegener I, Bender HJ (1968) Späte extrapyramidale Hyperkinesen bei neuroleptischer Langzeittherapie. Pharmacopsychiatry 1:169–195

    Article  Google Scholar 

  • Heinrich K, Tegeler J, Wöller W, Quadbeck H, Arendt G, Klieser E, Lange H, Lehmann E (1985) GABA-ergic treatment of tardive dyskinesia. In: Pichot P, Berger P, Wolf R, Thau K (eds) Psychiatry. The state of art, vol 2. Higher nervous activity. Plenum Press, New York London

    Google Scholar 

  • Hermesh H, Shalev A, Munitz H (1985) Contribution of adverse drug reaction to admission rates in an acute psychiatric ward. Acta Psychiatr Scand 72:104–110

    Article  PubMed  CAS  Google Scholar 

  • Hogarty GE (1984) Depot neuroleptics: the relevance of psychosocial factors. J Clin Psychiatry 45:34–42

    Google Scholar 

  • Hogarty GE, Schooler NR, Ulrich R, Mussare F, Ferro P, Herron E (1979) Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch Gen Psychiatry 36:1283–1294

    Article  PubMed  CAS  Google Scholar 

  • Jeste DV, Wyatt RJ (1981) Changing epidemiology of tardive dyskinesia: an overview. Am J Psychiatry 138:297–309

    Article  PubMed  CAS  Google Scholar 

  • Jeste DV, Wyatt RJ (1982) Therapeutic strategies against tardive dyskinesia. Guilford, New York

    Google Scholar 

  • Jeste DV, Potkin SG, Sindha S, Feder S, Wyatt RJ (1979) Tardive dyskinesia: reversible and persistent. Arch Gen Psychiatry 36:585–590

    Article  PubMed  CAS  Google Scholar 

  • Jeste DV, Wagner RL, Weinberger DR, Rieth KJ, Wyatt RJ (1980) Evaluation of CT scans in tardive dyskinesia. Am J Psychiatry 137:247–249

    PubMed  CAS  Google Scholar 

  • Jeste DV, Karson CN, Lager AC, Bigelow LB, Wyatt RJ (1984) Association of abnormal involuntary movements and negative symptoms. Psychopharmacol Bull 20:380–381

    PubMed  CAS  Google Scholar 

  • Jeste DV, Lohr JB, Clark K, Wyatt RJ (1988) Pharmacological treatments of tardive dyskinesia. J Clin Psychopharmacol 8:38–48

    Article  Google Scholar 

  • Johnson DAW (1984) Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia. J Clin Psychiatry 5:13–21

    Google Scholar 

  • Johnson DAW, Ludlow JM, Street K, Taylor RDW (1987) Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilised outpatients with schizophrenia. Br J Psychiatry 151:634–638

    Article  PubMed  CAS  Google Scholar 

  • Kane JM (1985) Antipsychotic drug side effects: their relationship to dose. J Clin Psychiatry 46:16–21

    PubMed  CAS  Google Scholar 

  • Kane JM, Smith JM (1982) Tardive dyskinesia prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry 39:473–481

    Article  PubMed  CAS  Google Scholar 

  • Kane JM, Woerner M, Weinhold P, Wegner J, Kinon B (1984) Incidence of tardive dyskinesia: five-year data from a prospective study. Psychopharmacol Bull 20:39–40

    PubMed  CAS  Google Scholar 

  • Kane JM, Woerner M, Sarantakos S (1986) Depot neuroleptics: a comparative review of standard, intermediate, and low-dose regimens. J Clin Psychiatry 47:30–33

    PubMed  Google Scholar 

  • Kane JM, Woerner M, Borenstein M, Wegner J, Lieberman J (1986) Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 22:254–258

    PubMed  CAS  Google Scholar 

  • Kane JM, Woerner M, Lieberman J (1988) Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharmacol 8:52–56

    Article  Google Scholar 

  • Keepers GA, Clappison VJ, Casey DE (1983) Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch Gen Psychiatry 40:1113–1117

    Article  PubMed  CAS  Google Scholar 

  • Lehmann E (1987) Neuroleptanxiolyse: Neuroleptika in Tranquilizerindikation. In: Pichot P, Möller HJ (Hrsg) Neuroleptika-Rückschau 1952–1986. Springer, Berlin Heidelberg New York Tokyo, S 111–118

    Google Scholar 

  • Lehmann E, Quadbeck H, Tegeler J, Fararuni M, Heinrich K (1980) Wirkungsdifferenzen bei Hoch- und Standarddosierung von Fluphenazin-Decanoat in Abhängigkeit von Patienten-Merkmalen. Pharmacopsychiatry 13:117–120

    Article  CAS  Google Scholar 

  • Manos N, Lavrentiadis G, Gkiouzepas J (1986) Evaluation of the need for prophylactic antiparkinsonian medication in psychotic patients treated with neuroleptics. J Clin Psychiatry 47:114–116

    PubMed  CAS  Google Scholar 

  • Marder SR, van Putten T, Mintz J, Lebell M, McKenzie J, May PRA (1987) Low- and conventional-dose maintenance therapy with fluphenazine decanoate. Two-year outcome. Arch Gen Psychiatry 44:518–521

    Article  PubMed  CAS  Google Scholar 

  • Marsden CD (1985) Is tardive dyskinesia a unique disorder? In: Casey DE, Chase TN, Christensen AV, Gerlach J (eds) Dyskinesia research and treatment. Psychopharmacology [Suppl 2] Springer, Berlin Heidelberg New York Tokyo

    Google Scholar 

  • Morselli PL, Fournier V, Bossi L, Musch B (1985) Clinical activity of GABA agonists in neuroleptic- and L-dopa-induced dyskinesia. In: Casey DE, Chase TH, Christensen AV, Gerlach J (eds) Dyskinesia. Research and treatment. Springer, Berlin Heidelberg New York Tokyo

    Google Scholar 

  • Munetz MR, Cornes CL (1982) Akathisia, pseudoakathisia and tardive dyskinesia: clinical examples. Compr Psychiatry 23:345–348

    Article  PubMed  CAS  Google Scholar 

  • Owens DGC, Johnstone EC, Crow DJ, Frith CD, Jagon JR, Kreel L (1985) Lateral ventricular size in schizophrenia: relationship to the disease process and its clinical manifestations. Psychol Med 15:27–41

    Article  PubMed  CAS  Google Scholar 

  • Pach J (1989) Tardive Dyskinesien nach Tranquilizerbehandlung mit einem niedrig dosierten Depot-Neuroleptikum (Fluspirilen 1,5 mg). Psycho 15:681–686

    Google Scholar 

  • Van Putten T, Marder SR (1986) Toward a more reliable diagnosis of akathisia. Arch Gen Psychiatry 43:1015–1016

    Article  PubMed  Google Scholar 

  • Van Putten T, May PRA, Marder SR (1984) Akathisia with haloperidol and thiothixene. Psychopharmacol Bull 20:114–116

    PubMed  Google Scholar 

  • Robinson ADT, McCreadie RG (1986) The nithsdale schizophrenia survey. V. Follow-up of tardive dyskinesia at 3 ½ years. Br J Psychiatry 149:621–623

    Article  PubMed  CAS  Google Scholar 

  • Rüther E, Haag M, von Oefele K, Keppler E, Haag H (1987) Späte extrapyramidale Hyperkinesen (Spätdyskinesien): Risiko der Neurolepsie? In: Pichot P, Möller HJ (Hrsg) Neuroleptika, Rückschau 1952–1986. Künftige Entwicklungen. Springer, Berlin Heidelberg New York Tokyo

    Google Scholar 

  • Schmidt LG (1989) Utilization and safety of fluspirilene in non-psychotic outpatients. Pharmacopsychiatry 22:188–191

    Article  PubMed  CAS  Google Scholar 

  • Schmidt LG, Langscheid-Schmidt K (1987) Neuroleptika-bedingte Aufnahmen in einer psychiatrischen Universitätsklinik. Nervenarzt 58:379–382

    PubMed  CAS  Google Scholar 

  • Siris SG (1985) Three cases of akathisia and „acting out“. J Clin Psychiatry 46:395–397

    PubMed  CAS  Google Scholar 

  • Sovner R, DiMascio A (1978) Extrapyramidal syndromes and other neurological side effects of psychotropic drugs. In: Lipton MA, DiMascio A, Killam KF (eds) Psychopharmacology: a generation of progress. Raven, New York

    Google Scholar 

  • Struve FA, Willner AE (1983) Cognitive dysfunction and tardive dyskinesia. Br J Psychiatry 143:597–600

    Article  PubMed  CAS  Google Scholar 

  • Tamminga CA, Gerlach J (1987) New neuroleptics and experimental antipsychotics in schizophrenia. In: Meltzer HY (ed) Psychopharmacology the third generation of progress. Raven, New York

    Google Scholar 

  • Tegeler J (1986) Depot-Neuroleptika und späte extrapyramidale Hyperkinesen. In: Heinrich K, Sieberns S (Hrsg) Internationales Fluanxol-Depot-Symposium, Das Ärztliche Gespräch 40. pmi, Frankfurt

    Google Scholar 

  • Tegeler J (1989) Klinik der Spätdyskinesien. In: Hippius H, Rüther E, Schmauss M (Hrsg) Katatone und dyskinetische Syndrome. Springer, Berlin Heidelberg New York Tokyo

    Google Scholar 

  • Tegeler J, Wöller W (1983) Therapeutische Maßnahmen bei späten extrapyramidalen Hyperkinesen. Fortschr Neurol Psychiatr 51:203–226

    Article  PubMed  CAS  Google Scholar 

  • Tegeler J, Wöller W (1986) Klinik und Therapie später extrapyramidaler Hyperkinesen. In: Laux G, Reimer F (Hrsg) Klinische Psychiatrie, Bd 2. Hippokrates, Stuttgart

    Google Scholar 

  • Tegeler J, Klieser K (1988) Neue Neuroleptika zur Behandlung schizophrener Erkrankungen. MMW 130:567–571

    Google Scholar 

  • Tegeler J, Lehmann E, Quadbeck H, Klieser E, Wöller W (1982) Experimenteller Vergleich niedriger und hoher Haloperidol-Dosen in der Behandlung akut schizophrener Patienten. Arzneimittelforschung 32:887–888

    Google Scholar 

  • Tegeler J, Bogerts B, Wurthmann C (1988) CT-Untersuchungen an schizophrenen Patienten mit späten Hyperkinesen. In: Beckmann H, Laux D (Hrsg) Biologische Psychiatrie. Springer, Berlin Heidelberg New York Tokyo

    Google Scholar 

  • Tegeler J, Strauss WH, Lüthcke H, Bertling R (1988) Cognitive functions in schizophrenic patients with tardive dyskinesia. Pharmacopsychiatry 21:308–309

    Article  PubMed  CAS  Google Scholar 

  • Tegeler J, Lehmann E, Weiher A, Heinrich K (1989) Tolerability of long-term treatment with fluspirilene 1.5 mg per week. Pharmacopsychiatry 22:218

    Google Scholar 

  • Tegeler J, Lehmann E, Heinrich K (1990) Neuroleptanxiolyse. Fluspirilen in niedriger Dosierung. MMW 132

    Google Scholar 

  • Toenniessen LM, Casey DE, McFarland BH (1985) Tardive dyskinesia in the aged. Arch Gen Psychiatry 42:278–284

    Article  PubMed  CAS  Google Scholar 

  • Waddington JL, Youssef HA, Molloy AG, OBoyle KM, Pugh MT (1985) Association of intellectual impairment, negative symptoms, and aging with tardive dyskinesia: clinical and animal studies. J Clin Psychiatry 46:29–33

    PubMed  CAS  Google Scholar 

  • Wegner JT, Kane JM, Weinhold P, Woerner M, Kinon B, Liebermann J (1985) Cognitive impairment in tardive dyskinesia. Psychiatr Res 16:331–337

    Article  CAS  Google Scholar 

  • Williams AO, Reveley MA, Kolakowska T, Ardern M, Mandelbrote BM (1985) Schizophrenia with good and poor outcome 2: cerebral ventricular size and its clinical significance. Br J Psychiatry 146:239–246

    Article  PubMed  CAS  Google Scholar 

  • Wöller W, Tegeler J (1983) Späte extrapyramidale Hyperkinesen. Klinik — Prävalenz — Pathophysiologic Fortschr Neurol Psychiatr 51:131–157

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Psychiatrische Klinik, Universität Düsseldorf, Bergische Landstraße 2, D-4000, Düsseldorf 11, Deutschland

    Priv.Doz. Dr. J. Tegeler

Authors
  1. Priv.Doz. Dr. J. Tegeler
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Psychiatrische Klinik, Rheinische Landesklinik, Heinrich-Heine-Universität, Bergische Landstr. 2, 4000, Düsseldorf 12, Deutschland

    Kurt Heinrich

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Tegeler, J. (1990). Extrapyramidale Nebenwirkungen bei neuroleptischer Therapie. In: Heinrich, K. (eds) Leitlinien neuroleptischer Therapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-93466-7_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-93466-7_13

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-52723-7

  • Online ISBN: 978-3-642-93466-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation